Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Medicenna Therapeutics Corp ( (TSE:MDNA) ) has provided an update.
Medicenna Therapeutics will present updated preclinical data at the AACR Annual Meeting 2026 on MDNA113, a first-in-class, tumor-targeted and conditionally activated anti-PD-1-IL-2 bifunctional Superkine designed to anchor in IL-13Rα2-overexpressing solid tumors. The in vivo and non-human primate data are expected to highlight MDNA113’s exceptional tumor selectivity, localization, and potency alongside improved systemic tolerability, underscoring its potential to expand the therapeutic window and address immunologically cold cancers such as pancreatic, liver, brain, breast, colon, ovarian and prostate tumors that collectively affect more than 2 million patients annually.
The most recent analyst rating on (TSE:MDNA) stock is a Sell with a C$0.69 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.
Spark’s Take on MDNA Stock
According to Spark, TipRanks’ AI Analyst, MDNA is a Neutral.
The score is primarily weighed down by weak financial performance (pre-revenue, ongoing losses and negative free cash flow with shrinking equity/assets) and bearish technicals (below major moving averages with negative momentum). Valuation is also constrained by the negative P/E and lack of dividend support.
To see Spark’s full report on MDNA stock, click here.
More about Medicenna Therapeutics Corp
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company developing novel, highly selective Superkines based on IL-2, IL-4 and IL-13 to treat cancer and autoimmune diseases. Its pipeline includes MDNA11, a long-acting IL-2 Superkine targeting effector T cells and NK cells, MDNA113, a first-in-class PD-1 x IL-2 bifunctional therapy for solid tumors, and bizaxofusp, an IL-4 Empowered Superkine that has received Fast Track and Orphan Drug designations for recurrent glioblastoma.
Average Trading Volume: 117,249
Technical Sentiment Signal: Sell
Current Market Cap: C$52.23M
For a thorough assessment of MDNA stock, go to TipRanks’ Stock Analysis page.